U..S. Patent and Tr

PTO/SB/05 (11-00) red for use through 10/31/2002. OMB 0651-0032 Office, U.S. DEPARTMENT OF COMMERCE

rk Reduction Act of 1995, no persons are require	d to respond
UTILITY	
PATENT APPLICATION	

TRANSMITTAL

valid OMB control number Attorney Docket No. 38-21(51837)B He, St v Sichuan First Inventor Title NUCLEIC ACID MOLECULES ASSOCIATED WITH PLANT CELL PROLIFERATION AND GROWTH AND USES THEREOF EK089244562US Everege Mail Label No.

ቜ:	TRANSMITTAL		LEIC ACID MOLECULES AS LIFERATION AND GROWTH					
Ē	Only for new nonprovisional applications under 37 CFR 1.53 (b))	Express Mail I		EK089244562U				
	APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application content.		DDRESS TO: Box	stant Commissio Patent Applicati hington, DC 202	on			
1.	X Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a dupticate for fee processing)	7	CD-ROM or CD-R Computer Program		· •			
3.	Applicant claims small entity status. X Specification [Total Pages 90] Descriptive title of the invention Cross References to Related Applications Statement Regarding Fed sponsored R and D	8	a. X Computer React b. Specification Sequence	ry) dable Form (CRF) <u></u>			
4	Reference to sequence listing, a table, or a computer program listing appendix Background of the Invention Brief Summary of the Invention Brief Description of the Drawings (If filed) Detailed Description		ACCOMPANYING A		PARTS			
	- Claim(s) - Abstract of the Disclosure X Drawing(s) (35 USC 113) [Total Sheets 19]			atement x	Power of Attorney			
5.	Oath or Declaration [Total Pages 6] 1	Information Disclo	sure	(if applicable) Copies of IDS			
	a. X Newly executed (original or copy) Copy from a prior application (37 CFR 1.63(d))	1:		dment	Citations			
	i. DELETION OF INVENTOR(S)	1.	(should be specifical)	y itemized)				
6.	15. ((f foreign priority is claimed) 15. ((f foreign priority is claimed) 16. ((f foreign priority is claim							
18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) of prior application No: Prior Application Information: Examiner: For CONTINUATION OR DIVISIONAL APPS ONLY: The entire disclosure of the prior application from which an oath or declaration is supplied under Box 80, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadverted by omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS								
Customer Number or Bar Code Label [Iniert Customer No. or attach Bar Code] or X Correspondence address below								
No	une Lawrence M. Lavin, Jr.							
Ļ	Patent Department, E2NA; Monsan	to Company						
Cř	ty St. Louis	State	Missouri	ZIP CODE	63167			
	ountry USA	Telephone	(314) 694-3602	FAX	(314) 694-1671			
⊨	ame (Print/Type) Lawrence M. Lavin, Jr.		Registration No. (Attor		30768			
Signature MINMIN MA								
_					7.70			

Burden Hour Statement. This form is estimated to take 2 bours to complete. Time will vary depending pon the needs of the individual cases. Any comments on the amount of time you required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Ocket No. 38-21(51837)B Inventor: Steve S. He et al.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Steve S. He et al.

Appln. No.: To Be Assigned

Filed:

Dec 19,2001

Nucleic Acid Molecules Associated With Plant Cell Proliferation And

Growth And Uses Thereof

Art Unit:

To Be Assigned

Examiner:

To Be Assigned

Atty. Docket: 38-21(51837)B



I hereby verify this transmittal together with the patent application referred to below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 Express Mail Label No. EK089244562US on the date indicated and is addressed to: Commissioner for Patens, Washington, D.C. 20231

Lawrence M. Lavin, Jr. Registration No. 30,768

Date Date

TRANSMITTAL OF NO

Box Patent Application

Commissioner for Patents

Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is the complete patent application of:

Nucleic Acid Molecules Associated With Plant Cell Proliferation And Growth And Uses

Thereof

Inventors: Steve S. He

Stanton B. Dotson

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- Utility Patent Application Transmittal (PTO/SB/05);
- 2. Form PTO/SB/17 (in duplicate);
- 3. U.S. Utility Patent Application entitled:

Nucleic Acid Molecules Associated With Plant Cell Proliferation And Growth And Uses Thereof

and naming as inventors:

Steve S. HE and Stanton B. DOTSON

the application consisting of:

- a. A specification containing:
 - (i) 85 pages of a description prior to the claims;
 - (ii) 4 page of claims (34 claims); and
 - (iii) a one (1) page abstract;
- 4. The computer readable form (CRF) containing the sequence listing information;
- 5. 2 CD-Rs (Copy 1, Copy 2) containing the Sequence listing;
- Drawings (19 pages);
- 7. Statement Regarding Sequence Submission;
- Combined Declaration and Power of Attorney, executed by inventor Steve S. He (3 pages);
- Combined Declaration and Power of Attorney, executed by inventor Stanton B. Dotson (3 pages);

It is respectfully requested that the attached prepaid postcard be stamped with the filing date and unofficial application number and returned as soon as possible.

Respectfully submitted,

Lawrence M. Lavin, Jr., Esq (Reg. No. 30,768

Enclosures

Date: 12/19/0/

Patent Department, E2NA Monsanto Company 800 N. Lindbergh Boulevard St. Louis, MO 63167 Tel: 636-694-3602

Fax: 636-694-1671

Date:



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known FEE TRANSMITTAL Application Number Filing Date for FY 2001 'n First Named Inventor H . Stev Sichuan -22 Patent fee are subject to annual revision Eveniner Name Group Art Unit TOTAL AMOUNT OF PAYMENT 1682 Attorney Docket No 38-21(51837)B METHOD OF PAYMENT (check one) 3. ADDITIONAL FEES The Commissioner is hereby authorized to charge indicated fees and credit any overnayments to: Fee Description Fee Paid 13-4125 105 130 205 65 Surcharge - late filing fee or oath ^ 50 227 25 Surcharge - late provisional filing fee or cover she 139 Non-English specification Charge Any Additional Fee Required under 37 CFR 1.16 and 1.17 2.520 147 2 520 For filing a request for ex part reexamination Applicant claims small entity status Requesting publication of SIR prior to Examiner action 112 0201 112 1.940* See 37 CFR 1.27 Requesting publication of SIR after Examiner action 112 1 9/04 112 1 940+ Payment Enclosed: 110 215 55 Extension for reply within first month Check Credit card Other 380 Extension for reply within second month 216 FEE CALCULATION 870 217 Extension for reply within third month 1. BASIC FILING FEE 680 118 1.360 218 Extension for reply within fourth month Large Entity Small 1.850 Extension for reply within fifth month 128 228 Fee Fee Fee description Code (\$) Code (\$) 119 300 219 150 Notice of Anneal n 101 710 201 355 Utility filing fee 710 120 300 220 150 Filing a brief in support of an appeal 106 320 206 160 Design filing fee 121 260 221 150 Request for Oral hearing 107 490 207 245 Plant filling fee 108 710 208 355 Reissue filing fee 1.510 138 1.510 Petition to institute a public use proceeding Provisional filing for 110 240 55 Petition to revive - unavoidable (\$) SUBTOTAL (1) 710 1.210 241 605 Petition to revive - unintentional 141 0 2. EXTRA CLAIM FEES 1 210 Utility issue fee (or reissue) 142 242 M Fee from Extra Claims helow Fee Pair 143 430 243 215 Design issue fee n Total Claims 34 .20** -14 X 18 252 144 430 243 215 Plant issue fee n Independent Claims 12 - 3**= 9 80 720 122 122 Petitions to commissioner Multiple Dependent 123 123 Processing under 37 CFR 1.17(q) 50 ** or number previously paid, if greater; For reissues, see below Submission of information Disclosure Statement 126 240 126 240 n Entity Entity Fee description Fee Fee 581 581 40 Recording each patent assignment per property (times number of properties) n Code (\$) Code (\$) 103 18 203 Claims in excess of 20 146 690 246 345 Filing a submission after final rejection (37 CFR §1.129(a)) n 102 8n 202 Independent claims in excess of 3 690 249 For each additional invention to be examined (37 CFR §1.129(b)) 104 270 204 Multiple dependent claims, if not paid 109 209 ** Reissue independent claims over original patent 179 279 345 Request for continued Examination (RCE) 0 18 ** Reissue claims in excess of 20 110 210 169 900 169 Request for expedited examination of a design application n and over original patent Other fee (specify) SUBTOTAL (2) (\$) 972 SUBTOTAL (3) ** or number previously paid, if greater; For reissues, see abive *Reduced by Basic Filing Fee Paid SUBMITTED BY Complete (if applicable) 30768 Name (Print/Type) Re M. Lavin Law Registration No. (Attorney/Agent) Telephone (314) 694-3602

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

Burden Hour Statement. This form is estimated to take 2 hours to complete. Time will vary depending pon the needs of the individual cases. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETE PORNS TO THIS ADDRESS SEND TO. Assistant Commissioner for Patients, Washington, DC 20231.

Signature

PTO/SB/17 (11-00)
Aptrove use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2001 Patent fee are subject to annual revision. Complete if Known Application Number Filing Date First Named Inventor First Name Examiner Name Examiner Name

TOTAL AMOUNT OF BANDATHE		Group Art Unit							
TOTAL AMOUNT OF PAYMENT (S)	1682		Atto	rney l	Docket	No.	3	8-21(51837)B	20
METHOD OF PAYMENT (check of	ne)								<u> </u>
1. X The Commissioner is hereby authorized to charge		3. AD	DITIO	NAL	FEES				
Deposit Deposit		Large Fee Code	Entity Fec (\$)	Small Fee Code	Entity Fec (\$)		Fee Description	1	Fee Paid
Account Number 13-4125		105	130	205	65	Surcharge -	narge - late filing fee or oath		
Deposit Account	\neg	127	50	227	25		- late provisional filin	e fee or cover sh	. ==
Name		139	130	139	130		h specification	B	0
X Charge Any Additional Fee Required under 37 CFR 1.16 and 1.17			2,520	147	2,520	-	request for ex part ree	vamination	
Applicant claims small entity status.		112	920*	112	1,840*		publication of SIR pri-		
See 37 CFR 1.27			1,840*	113	1,840*		publication of SIR afte		
2. Payment Enclosed:	-	115	110	215	55				" 0
Check Credit card Order	Other						for reply within first n		
FEE CALCULATION		116	380	216	190		for reply within secon		0
1. BASIC FILING FEE		117	870	217	435		for reply within third		
Large Entity Small Entity		118	1,360	218	680	Extension	for reply within fourth	month	0
Fee Fec Fee Fee Fee description Code (\$) Code (\$)		128	1,850	228	925	Extension	for reply within fifth r	nonth	0
101 710 201 355 Utility filing fee	710	119	300	219	150	Notice of /	Appeal		0
106 320 206 160 Design filing fee		120	300	220	150	Filing a bri	ief in support of an ap	peal	0
107 490 207 245 Plant filing fee		121	260	122	150	Request fo	r Oral hearing		0
108 710 208 355 Reissue filing fee		138	1,510	138	1,510	Petition to i	nstitute a public use p	roceeding	0
114 150 214 75 Provisional filing fee		140	110	240	55	Petition to	revive - unavoidable		0
SUBTOTAL (1) (\$	710	141	1,210	241	605	Petition to	revive - unintentional		0
2. EXTRA CLAIM FEES Fee from		142	1,210	242	605	Utility issu	e fee (or reissue)		0
Extra Claims below	Fee Paid	143	430	243	215	Design iss	sue fee		0
Total Claims 34 -20** = 14 X 18	= 252	144	430	243	215	Plant issue	e fee		
ndependent Claims 12 - 3** = 9 X 80 dultiple Dependent 270	= 720	122	130	122	130	Petitions t	o commissioner		0
*dultiple Dependent 270 * or number previously paid, if greater; For reissues, see below	,	123	50	123	50	Processin	g under 37 CFR 1.176	(a)	0
Large Entity Small Entity		126	240	126	240		n of information Disc		
Fee Fee Fee Fee Fee description Code (\$) Code (\$)		581	40	581	40		ng each patent assignm number of properties)		0
103 18 203 9 Claims in excess of 20	i	146	690	246	345	Filine a s	ubmission after final r R §1.129(a))		0
102 80 202 40 Independent claims in ea		149	690	249	345	For each a	dditional invention to	be examined	0
104 270 204 135 Multiple dependent claim 109 80 209 40 ** Reissue independent		179	690	279	345	(37 CFI	R §1.129(b))		
over original patent							or continued Examinat		
110 18 210 9 ** Reissue claims in ex and over original patent	cess of 20	169	900	169	900	Request for of a des	or expedited examinat ign application	ion	0
SUBTOTAL (2) (\$) 972		Other fee (specify)						- []	
** or number previously paid, if greater; For reissues, see a	bive	*Reduce	d by Bas	ic Filing	g Fee Pai	đ	SUBTO	TAL (3)	\$) 0
SUBMITTED BY Complete (if applicable)									
Name (Print/Type) Lawrence M. Lavin, Ir	5/	Res	istratio	n No. (Attorne	(Agent)	30768		(314) 694-3602

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

Burden Hour Statement. This form is estimated to take 2 hours to complete. Time will vary depending not the redeed of the individual cases. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMST OTHIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Washington, DC 20231.